Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
Drug resistance to cancer therapy is an important cause of high mortality in cancer patients. Intratumoral and intertumoral heterogeneity is an important reason for tumor resistance. Therefore, choosing a combination therapy method during cancer therapy can effectively inhibit different subtypes of cancer cells and avoid tumor recurrence after therapy. In the process of cancer glucose metabolism reprogramming, the heterogeneity and flexibility of glucose metabolism of cancer cells make targeted therapy for cancer glucose metabolism need to target multiple regulatory metabolic pathways at the same time or use in combination with other therapeutic methods to achieve cancer clearance effect of cells. CD BioGlyco provides solutions to all problems in the process of traditional radiotherapy and chemotherapy combined with targeted cancer glucose metabolism therapy.
Fig. 1 Acquired chemoradiotherapy resistance mediated by metabolic reprogramming (Lin J, et al., 2019)
What We Do
- One-stop glucose metabolism intervention chemotherapy combination therapy development management
Chemotherapy is the most widely used method of cancer treatment. However, chemotherapy resistance has become an important cause of death in cancer patients. Studies have shown that reprogramming glucose metabolism can induce tumor chemotherapy resistance. The activation or inactivation of chemotherapy-resistance-related signaling pathways during abnormal glucose metabolism and the reprogramming of glucose metabolism mediated by oncogenes all affect the therapeutic effect of chemotherapy. Therefore, as a leading cancer glucose metabolism researcher, CD BioGlyco provides a one-stop solution for glucose metabolism intervention and chemotherapy combined therapy development.
The specific services we can provide are as follows, including but not limited to:
- Analysis of the mechanism of glucose metabolism-mediated chemoresistance
- Screening of combined treatment strategies of glucose metabolism intervention and chemotherapy
- One-stop glucose metabolism intervention radiotherapy combination therapy development management
A large number of studies have shown that the metabolic reprogramming of cancer cells is an important reason for the radioresistance of cancer. Cancer cells adapt to ionizing radiation through a series of changes in glucose metabolism. Cancer cells shift to a glycolytic phenotype, upregulate glucose transporter expression, increase lactate accumulation, and induce radioresistance by altering mitochondrial energy metabolism profile and function. Therefore, glucose metabolism pathway interventions combined with radiotherapy may show more surprising effects in cancer treatment. CD BioGlyco provides a one-stop solution for glucose metabolism intervention and radioresistance combined therapy development.
The specific services we can provide are as follows, including but not limited to:
- Analysis of the mechanism of glucose metabolism-mediated radioresistance
- Development of novel radiosensitizers based on glucose metabolism
- One-stop glucose metabolism intervention immunotherapy combination therapy development management
Both cancer cells and immune cells undergo reprogramming of glucose metabolism, and the overlap of metabolic changes between cancer cells and immune cells affects the efficacy of immunotherapy. Immunotherapy includes a variety of strategies. Among them, the development and optimization problems related to chimeric antigen receptor T cell therapy that we can solve based on glucose metabolism reprogramming have been introduced. If you want to know more information, please click on this page. CD BioGlyco provides a one-stop solution for glucose metabolism intervention and immunotherapy combined therapy development.
The specific services we can provide are as follows, including but not limited to:
- Screening of combined treatment strategies of glucose metabolism intervention and immune checkpoint inhibitors
- Analysis of the mechanism of glucose metabolism intervention to enhance immune checkpoint inhibitors
Our Advantages
- We have a small animal radiation research platform, which can conduct in vivo research on glucose metabolism intervention combined with radiotherapy.
- We have a multi-omics technology platform MOPCGM, which enables high-throughput screening of glucose metabolism intervention targets.
CD BioGlyco can utilize the MOPCGM platform to provide an optimal solution for the discovery of combined therapeutic strategies for glucose metabolism. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
Reference:
- Lin J, et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res. 2019; 38(1): 218.
